Navigation Links
LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
Date:2/1/2010

rious adverse events reported. The trials were initiated and run by Peplin, Inc., acquired by LEO Pharma in September 2009.  

Results from REGION I and Ib will be presented at an upcoming meeting of the American Academy of Dermatology.

LEO Pharma expects to file for regulatory approval of the treatment in the U.S. and Europe in 2011.

About Actinic Keratosis

Actinic keratosis (AK) is a common pre-cancerous skin condition caused by sun exposure, which can develop into skin cancers if left untreated. The number of AK patients is both large and rapidly growing, and AK is a serious health problem.

About LEO Pharma

Founded more than 100 years ago, LEO Pharma is an independent, research-based specialty pharmaceutical company committed to the discovery and development of novel drugs for patients within the areas of Dermatology and Critical Care Medicine. Wholly owned by The LEO Foundation, the company is headquartered in Ballerup, Denmark, outside of Copenhagen, and is represented in more than 90 countries worldwide.  Employees number more than 3,000, with 550 scientists and specialists working to develop new chemical entities.

With a strong portfolio of approved products and a robust pipeline of treatments in development for conditions including psoriasis, eczema and actinic (solar) keratosis, LEO Pharma is one of the leading dermatology companies in the U.S. and the world.  

For more information about LEO Pharma, visit www.leopharma.com.

SOURCE LEO Pharma

RELATED LINKS'/>"/>

SOURCE LEO Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
8. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... 2015  Profil Institute for Clinical Research, Inc., a clinical ... today a new textbook,  Translational Research Methods for Diabetes, ... leading global scientific publisher. The textbook is ... use in early phase clinical studies of new drugs ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition of ... by End User - Global Forecast to 2019" report ... market is valued at $1,228.58 million in 2014 and is ... $2,230.72 million by 2019. Allergy diagnostics is used to determine ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ... following a final approval from the US Food ... New Drug Application (ANDA) for generic Acular® opthalmic ... This strength of ketorolac is therapeutically equivalent to ...
... Althea Technologies, Inc., a leading provider of ... the addition of customized Formulation Development to the ... by the newly appointed Dr. James Matsuura, Director ... team of formulation and analytical scientists, along with ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... kidney transplant recipients need to take immunosuppressive drugs for the ... the thousands who have undergone transplantation, have been able to ... studying these rare individuals have identified a pattern of genes ... day be used to help identify other transplant recipients who ...
... about beta blockers making COPD worse are unfounded, experts ... tradition says that the beta blockers used to treat ... have severe lung disease, but a new Dutch study ... more than 2,200 people with chronic obstructive pulmonary disease ...
... ... President and Chief Executive Officer, is a finalist for the Ernst & Young Entrepreneur of ... ... Pentec Health Incorporated announced today that Joe Cosgrove, President and Chief Executive Officer, is ...
... Medicine for the first time have determined that bone marrow ... the bone marrow a potential therapeutic target, especially in people ... of the respiratory tract, cells produced by the bone marrow ... help fight infection. The data are published in the current ...
... University ... Mind Project. The Developing Mind Project aims to discover fundamentals of early learning and ... ... Learning & Brain Sciences (I-LABS) today announced the launch of a multi-year, multimillion-dollar initiative ...
... ... offered leadership and guidance about the transition from paper to electronic medical records for ... was held in mid-May. , ... Dearborn, MI (Vocus) May 24, 2010 -- Secure-24 and ATMP offered leadership ...
Cached Medicine News:Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 3Health News:Heart Drugs Safe for Lungs, Study Finds 2Health News:Heart Drugs Safe for Lungs, Study Finds 3Health News:Joseph Cosgrove Named as E&Y Entrepreneur Of The Year Finalist in the Greater Philadelphia Region 2Health News:Joseph Cosgrove Named as E&Y Entrepreneur Of The Year Finalist in the Greater Philadelphia Region 3Health News:Mount Sinai discovers bone marrow plays critical role in enhancing immune response to viruses 2Health News:University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project 2Health News:University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project 3Health News:University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project 4Health News:ATMP and Secure-24 Offer Physicians Leadership and Guidance for Electronic Medical Records 2Health News:ATMP and Secure-24 Offer Physicians Leadership and Guidance for Electronic Medical Records 3
... The NOW® Malaria Test is a field or ... Malaria infection. It is intended for the detection ... and an antigen that is common to all ... (P.f.), Plasmodium vivax (P.v.), Plasmodium ...
... Central Station provide an example of the ... cath or electrophysiology lab to healthcare professionals ... providing both physiomonitoring parameters and electronic charting ... on its own network. Witts Central Station ...
For the critical care environment, telemetry, emergency room and other monitoring areas....
DS 7600 Central Station...
Medicine Products: